| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Topalian SL | |
| Yang JC | |||
| Schwartzentruber DJ | |||
| Parkinson DR | |||
| Steinberg SM | |||
| Marincola FM | |||
| White DE | |||
| Hwu P | |||
| Royal RE | |||
| Heywood G | |||
| Krouse RS | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 91-98 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | The Cancer Journal from Scientific American | Q27714220 |
| P1476 | title | Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma | |
| P478 | volume | 2 |
| Q35196765 | Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience |
| Q38013803 | Cutting edge in medical management of cutaneous oncology |
| Q33415481 | Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program |
| Q37581762 | HPV as a model for the development of prophylactic and therapeutic cancer vaccines. |
| Q59400683 | High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 |
| Q36363721 | High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. |
| Q37346248 | High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. |
| Q50004232 | IL-2 and Beyond in Cancer Immunotherapy |
| Q37410551 | IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients |
| Q26774682 | Insight to drug delivery aspects for colorectal cancer |
| Q56899396 | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| Q24798836 | Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling |
| Q35162803 | Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. |
| Q34536176 | Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer |
| Q37369958 | The application of high-dose interleukin-2 for metastatic renal cell carcinoma |
| Q35044419 | The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma |
| Q39801051 | Treatment of cutaneous melanoma: current approaches and future prospects. |
| Q37129949 | Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines |
Search more.